ЭФФЕКТИВНОСТЬ И ПЕРЕНОСИМОСТЬ: РЕЗУЛЬТАТЫ ДВОЙНОГО СЛЕПОГО ПЛАЦЕБО-КОНТРОЛИРУЕМОГО И ПРОДЛЕННОГО ОТКРЫТОГО ИССЛЕДОВАНИЯ ОЦЕНКИ ДОЛГОВРЕМЕННОЙ БЕЗОПАСНОСТИ И ЭФФЕКТИВНОСТИ ПЕРАМПАНЕЛА В РФ
About the Author
P. N. Vlasov
Moscow State University of Medicine and Dentistry
Russian Federation
References
1. Karlov V.A. Farmakorezistentnost' i tolerantnost'. V kn. Epilepsiya u detei i vzroslykh zhenshchin i muzhchin. Rukovodstvo dlya vrachei. M. 2010; 667-676.
2. Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Currents. 2011; 11: 56-63.
3. Hanada T., Hashizume Y., Tokuhara N., Takenaka O., Kohmura N. et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011; 52: 1331-1340.
4. Steinhoff B.J., Ben-Menachem E., Ryvlin P., Shorvon S., Kramer L. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia. 2013; 54 (8): 1481-1489.
For citations:
Vlasov P.N.
. Epilepsy and paroxysmal conditions. 2014;6(5):10-12.
(In Russ.)
Views:
621